Request Appointment
12902 Usf Magnolia DrTampa, FL 33612
Fax+1 813-449-6713
Overview of Dr. Hansen
Dr. Doris Hansen is an oncologist in Tampa, FL and is affiliated with H. Lee Moffitt Cancer Center and Research Institute. She received her medical degree from St. George's University School of Medicine and has been in practice 8 years. She is one of 172 doctors at H. Lee Moffitt Cancer Center and Research Institute who specialize in Oncology. She has more than 40 publications and over 400 citings.
Education & Training
University of Mississippi Medical CenterFellowship, Hematology and Medical Oncology, 2018- University of Mississippi Medical CenterResidency, Internal Medicine, 2012 - 2015
St. George's University School of MedicineClass of 2012
Certifications & Licensure
FL State Medical License 2019 - 2026
MS State Medical License 2015 - 2018
American Board of Internal Medicine Internal Medicine- American Board of Internal Medicine Hematology
- American Board of Internal Medicine Medical Oncology
Clinical Trials
- Multiple Myeloma Outcomes Based on Maintenance Therapy Post Autologous Stem Cell Transplant Start of enrollment: 2022 Apr 20
Roles: Contact, Principal Investigator
Publications & Presentations
PubMed
- 1 citationsComparison of Standard-of-Care Idecabtagene Vicleucel and Ciltacabtagene Autoleucel in Relapsed/Refractory Multiple Myeloma.Doris K Hansen, Lauren C Peres, Danai Dima, Alicia Richards, Leyla Shune
Journal of Clinical Oncology. 2025-05-01 - Enhanced CAR-T Function and Mitochondrial Fitness from Earlier Unfractionated Stem Cell Product in Multiple Myeloma.Ciara L Freeman, Julieta Abraham-Miranda, Meghan Menges, Reginald M Atkins, Jerald Noble
Molecular Therapy. 2025-04-18 - Cardiovascular adverse events and outcomes after anti-BCMA CAR-T for relapsed and refractory multiple myeloma.Stefanie Palfi, Lauren C Peres, Himara Koelmeyer, Melissa Alsina, Rachid C Baz
Blood Cancer Journal. 2025-04-14
Press Mentions
One CAR T-cell Therapy for Multiple Myeloma Tops Another in Propensity Matched StudyDecember 11th, 2024- Moffitt Study Explores Key Risk Factors to Better Personalize CAR T-cell TherapyDecember 2nd, 2024
- J&J, Legend Solidify Carvykti's Lead in Earlier Multiple Myeloma with Strong Survival ShowingSeptember 30th, 2024
- Join now to see all
Viewing the full profile is available to verified healthcare professionals only.
Find your profile and take control of your online presence:
